A Phase 2 interventional study of CM512 and Placebo in Chronic Rhinosinusitis With Nasal Polyposis, sponsored by Beijing Keymed Biosciences Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Beijing Keymed Biosciences Co., Ltd. (part of Keymed Biosciences Co.Ltd) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Rhinosinusitis with a site in China — 18 open to participants now, 25 under way, 7 of them phase 3. Rhinosinusitis · China.
Among the 40 studies in Rhinosinusitis with a site in China, this one is the 16th largest by enrollment of the 36 interventional ones that give a count, is one of 10 that started in 2025, is one of 12 in phase 2, and was the 26th registered.
251 studies on the registry are indexed under Rhinosinusitis; 69 are open to participants now.
Browse Rhinosinusitis studies →18 of the 40 studies in Rhinosinusitis with a site in China are open now. Recruiting first, the newest first:
AstraZeneca · Sites in China
Ages 18+
Bambusa Therapeutics · Sites in China
Ages 18–75 · Healthy volunteers
Tang-Du Hospital · Sites in China
Ages 18–65
VivaVision Biotech, Inc · Sites in China
Ages 18–55 · Healthy volunteers
Guangdong Hengrui Pharmaceutical Co., Ltd · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 33 Rhinosinusitis studies recruiting now, 14 (42%) set no upper age limit and 13 (39%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 16 · Phase 3 11 · Phase 4 3
First in 2014; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 74 across 177 interventional studies indexed under Rhinosinusitis.
Median enrollment 117 across the 36 interventional studies, 75 across the 4 observational. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 40 have an industry lead sponsor. The 10 most frequent:
This study is registered under Beijing Keymed Biosciences Co., Ltd., one of the names counted as Keymed Biosciences Co.Ltd. Under that name alone:
Beijing Keymed Biosciences Co., Ltd. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Keymed Biosciences Co.Ltd has 7 studies filed under Rhinosinusitis — fewer than ten, so there is no comparison to draw.
9 of the studies in Rhinosinusitis with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07424144Phase 3SanofiAn Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps | 2027-02-17 |
| NCT07107256Phase 3Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps | 2027-03 |
| NCT06338995Phase 3Eli Lilly and CompanyA Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) | 2027-05 |
| NCT07807826Phase 3Beijing Keymed Biosciences Co., Ltd.A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (NEZHA-3) | 2027-11 |
| NCT07313917Longbio PharmaA Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 2027-02-28 |
Add all 9 to your calendar (.ics) → With an account.
Among the 40 studies in Rhinosinusitis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, randomized, double blind, placebo-controlled Phase II study to evaluate the efficacy and safety of CM512, and to observe the life quality of subjects, the Pharmacokinetics, Pharmacodynamics and immunogenicity of CM512 in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP).
The study consists of a Screening Period (up to 4 weeks), Treatment Period (24 weeks for double-blind treatment period) and Safety Follow-up Period (12 weeks).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: CM512
Biological: CM512
Biological: CM512
Drug: Placebo
Administered subcutaneous injection
Administered subcutaneous injection
Nasal Polyps Score (NPS)
Change from baseline in the Nasal Polyps Score (NPS) at week 24. NPS score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.
Time frame: at week 24
Change from baseline in NPS at other evaluation visits
Time frame: baseline up to week 36
Change from baseline in Nasal Congestion Score (NCS) at each evaluation visit
Time frame: baseline up to week 36
Proportion of subjects achieving an improvement in NPS from baseline of ≥ 1 point and ≥ 2 points at each evaluation visit
Time frame: baseline up to week 36
Change from baseline in Total Symptom Score (TSS) at each evaluation visit
Time frame: baseline up to week 36
Change from baseline in loss-of-smell (LoS) score at each evaluation visit
Time frame: baseline up to week 36
Change from baseline in Lund-Mackay (LMK) score evaluated by sinus computed tomography (CT) at each evaluation visit
Time frame: baseline up to week 36
Change from baseline in 22-item Sino-nasal Outcome Test (SNOT-22) score at each evaluation visit
Time frame: baseline up to week 36
Incidence of adverse events (AEs)
Time frame: baseline up to week 36
Physical examination
Time frame: baseline up to week 36
Vital signs
Time frame: baseline up to week 36
12-lead electrocardiogram (ECG)
Time frame: baseline up to week 36
clinical laboratory tests
Time frame: baseline up to week 36
Plasma concentrations of CM512
Time frame: baseline up to week 36
Change from baseline and percent change from baseline in serum total immunoglobulin E (IgE) level at each evaluation visit
Time frame: baseline up to week 36
Change from baseline and percent change from baseline in peripheral blood eosinophil (EOS) level at each evaluation visit
Time frame: baseline up to week 36
Change from baseline and percent change from baseline in serum interleukin-5 (IL-5) level at each evaluation visit
Time frame: baseline up to week 36
Change from baseline and percent change from baseline in serum interleukin-13 (IL-13) level at each evaluation visit
Time frame: baseline up to week 36
Change from baseline and percent change from baseline in serum thymic stromal lymphopoietin (TSLP) level at each evaluation visit
Time frame: baseline up to week 36
Change from baseline and percent change from baseline in serum thymus and activation-regulated chemokine (TARC) level at each evaluation visit
Time frame: baseline up to week 36
Change from baseline and percent change from baseline in serum eotaxin-3 level at each evaluation visit
Time frame: baseline up to week 36
Change from baseline and percent change from baseline in serum chemokine 13 (CCL13) level at each evaluation visit
Time frame: baseline up to week 36
Change from baseline and percent change from baseline in serum chemokine 22 (CCL22) level at each evaluation visit
Time frame: baseline up to week 36
Change from baseline and percent change from baseline in serum periostin level at each evaluation visit
Time frame: baseline up to week 36
Change from baseline and percent change from baseline in EOS levels in nasal polyp biopsy tissue
Time frame: baseline up to week 24
Incidence of Anti-drug antibodies (ADAs) and neutralizing antibodies (Nabs)
Time frame: baseline up to week 36
Change from baseline in Asthma Control Questionnaire-6 (ACQ-6) score at each evaluation visit in subjects coexisting asthma
Time frame: baseline up to week 36
Change from baseline in pre-bronchodilator forced expiratory volume in 1 second (FEV1) at each evaluation visit in subjects coexisting asthma
Time frame: baseline up to week 36
Ran from Jun 2025 to primary completion in Apr 2026, 10 months.
Of 16 phase 2 interventional studies under Rhinosinusitis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 26. This study's 10 months is below that.
Start moved once since we started tracking on Sep 25, 2026: May 2025 → Jun 2025, on Nov 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CM512